Biotechnology News and Research

RSS

Windhover Information selects Oncothyreon's PX-866 among top 10 oncology projects for partnering

Oncothyreon Inc. today announced that the Company's product candidate PX-866, a PI-3 kinase inhibitor, has been selected by Windhover Information, Inc., as one of the Top 10 most promising oncology projects in development that is available for partnering.

16 Nov 2009

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).

16 Nov 2009

Advanced Cell Technology to raise funds through private placements

Advanced Cell Technology, Inc., announced today that it has entered into definitive agreements on three private placements with institutional and other accredited investors under which the Company has received definitive commitments in excess of $15 million.

16 Nov 2009

Yongye International revenues increases 60.9% year-over-year in third quarter 2009

Yongye International, Inc. a leading manufacturer, developer and distributor of Shengmingsu brand plant and animal nutrient products in the People's Republic of China (PRC), today reported its financial results for the quarter ended September 30, 2009.

16 Nov 2009

Normal synaptic activity in nerve cells protects brain from Huntington's disease

Investigators at Burnham Institute for Medical Research (Burnham), the University of British Columbia's Centre for Molecular Medicine and Therapeutics and the University of California, San Diego have found that normal synaptic activity in nerve cells (the electrical activity in the brain that allows nerve cells to communicate with one another) protects the brain from the misfolded proteins associated with Huntington's disease.

16 Nov 2009

Potential of the European Biomarker Analysis Market to be the focus at upcoming Analyst Briefing

The "omics" revolution of the last decade has ensured that the field of biomarker research will test the frontiers of biomedical research in the coming years. New biomarkers are discovered each day and this rapid development promises excellent growth potential for the biomarker analysis market. However, due to various challenges faced in biomarker validation and assay development, there is a huge lag between the time that a biomarker is discovered in the laboratory and the time it is actually commercialized.

16 Nov 2009

Phase I clinical study for ETC-1002 commenced

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.

16 Nov 2009

Kun Run Biotechnology net revenue increases 65% for the quarter ended September 30, 2009

Kun Run Biotechnology, Inc., a leading bio-pharmaceutical company in China that focuses on manufacturing and sales of peptides and peptide-based drugs, today announced its financial results for the third quarter ended September 30, 2009.

13 Nov 2009

Pro-Pharmaceuticals announces financial results for the third quarter and first nine months of fiscal 2009

Pro-Pharmaceuticals, Inc., a developer of galectin-targeted, carbohydrate therapeutic compounds to treat cancer and fibrosis, today reported its financial results for the third quarter and first nine months of fiscal 2009. These results are included in the Company’s Quarterly Report on Form 10-Q for the three- and nine-month periods ended September 30, 2009, which has been filed with the SEC.

13 Nov 2009

Millar Instruments and Harvard Apparatus announce a new distribution partnership

Millar Instruments, Inc. developer and manufacturer of Mikro-Tip® pressure transducer catheters and pressure-volume (P-V) systems and Harvard Apparatus, manufacturer of specialty life science equipment, today announced a new distribution partnership.

13 Nov 2009

Emergent BioSolutions acquires 55,000 square foot manufacturing facility from MdBio Foundation

Emergent BioSolutions Inc. announced today that it has completed the acquisition of a 55,000 square foot manufacturing facility from MdBio Foundation and the land on which the facility stands from the City of Baltimore for a total purchase price of $8.2 million. The facility, located within the City of Baltimore, Maryland, previously operated as a Food and Drug Administration (FDA) licensed facility used by an experienced contract manufacturing organization (CMO) to produce a number of FDA approved products.

13 Nov 2009

Third quarter 2009 financial results announced by Soligenix

Soligenix, Inc., (Soligenix or the Company) (OTC Bulletin Board: SNGX), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today its financial results for the third quarter of 2009.

13 Nov 2009

CNS Pharmaceuticals' common shares sponsored by 886 AG on the electronic trading platform Xetra

CNS PHARMACEUTICALS AG, (C35.F) a developer and marketer of patented natural nutraceutical products is pleased to announce that the Company’s common shares is sponsored by the German Securities Trading Bank 886 AG Wertpapier Handelsbank on the electronic trading platform Xetra.

13 Nov 2009

Global industry leaders to address key trends in bioscience industry at Biotech 2009

Biotech 2009 (www.biotech2009.org) will bring together globally-recognized industry leaders to address key trends and topics relevant to the growth and advancement of the tri-state region’s bioscience industry.

13 Nov 2009

Pharmacyclics to present clinical updates and posters relating to PCI-24781 and PCI-32765

Pharmacyclics, Inc. today announced that posters related to PCI-24781 and PCI-32765 have been selected for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH), December 5-8, 2009 in New Orleans, LA.

13 Nov 2009

Clinical Care Options to provide online continuing medical education in "The Oncology Portal"

Clinical Care Options (CCO), a leader in the development of innovative interactive online, print, and live medical education for healthcare professionals, today announced its exclusive collaboration with Oncology Today(TM), a wholly owned subsidiary of US Oncology, Inc., to be the provider of online continuing medical education (CME) for the newly formed US Oncology's online clinician community, "The Oncology Portal."

13 Nov 2009

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

13 Nov 2009

New and effective medicines underway for treating a wide range of diseases affecting women

Women's Health Weekly recently reported that America's pharmaceutical research and biotechnology companies are working on nearly 1,000 life-changing medicines for diseases affecting women, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). The medicines are awaiting approval by the U.S. Food and Drug Administration or are in human clinical trials.

13 Nov 2009

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain.

13 Nov 2009

Adolor commences clinical testing of its oral mu opioid receptor antagonist

Adolor Corporation today announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD). The Phase 1, single ascending dose trial in healthy volunteers will assess safety and tolerability of the compound and will be followed by a multiple ascending dose study in early 2010.

13 Nov 2009

Biotechnology News and Research

Windhover Information selects Oncothyreon's PX-866 among top 10 oncology projects for partnering

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Advanced Cell Technology to raise funds through private placements

Yongye International revenues increases 60.9% year-over-year in third quarter 2009

Normal synaptic activity in nerve cells protects brain from Huntington's disease

Potential of the European Biomarker Analysis Market to be the focus at upcoming Analyst Briefing

Phase I clinical study for ETC-1002 commenced

Kun Run Biotechnology net revenue increases 65% for the quarter ended September 30, 2009

Pro-Pharmaceuticals announces financial results for the third quarter and first nine months of fiscal 2009

Millar Instruments and Harvard Apparatus announce a new distribution partnership

Emergent BioSolutions acquires 55,000 square foot manufacturing facility from MdBio Foundation

Third quarter 2009 financial results announced by Soligenix

CNS Pharmaceuticals' common shares sponsored by 886 AG on the electronic trading platform Xetra

Global industry leaders to address key trends in bioscience industry at Biotech 2009

Pharmacyclics to present clinical updates and posters relating to PCI-24781 and PCI-32765

Clinical Care Options to provide online continuing medical education in "The Oncology Portal"

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

New and effective medicines underway for treating a wide range of diseases affecting women

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

Adolor commences clinical testing of its oral mu opioid receptor antagonist

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News